Sylvia Hsu, MD
Dermatology · Philadelphia, PANPI 1548340805
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $37,207 of the $40,726 with a category attached, or 91.4%. It is spread thinly across 19 manufacturers, the largest accounting for just 23.2%. Reporting peaked in 2024 at $11,895 and has fallen 95.6% since, to $525 in 2025. Among dermatology clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 100 payments — averaging $407.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$9K
- Galderma Laboratories, L.p.$8K
- Boehringer Ingelheim$6K
- Lilly USA, LLC$5K
- Sanofi$4K
- Ortho Dermatologics, A Division Of Bausch Health US, LLC$4K
- plus $4K from 13 others
Across 76 payments — averaging $2905.97 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$88K
- Argenx US, Inc.$56K
- Regeneron$46K
- Novartis$31K
- Bristol Myers Squibb$827
What the payments were for
- Consulting fees$37,20791%
- Travel & lodging$5791%
- Food & beverage$2,9417%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 17 | $9,431 |
| Galderma Laboratories, L.p. | 1 | $8,163 |
| Boehringer Ingelheim | 4 | $6,066 |
| Lilly USA, LLC | 4 | $4,638 |
| Sanofi | 6 | $4,421 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 2 | $3,534 |
| LEO Pharma Inc. | 2 | $2,380 |
| AbbVie | 38 | $1,003 |
| Novartis | 7 | $350 |
| Regeneron Healthcare Solutions, Inc. | 4 | $140 |
| Bristol Myers Squibb | 1 | $137 |
| Sanofi-aventis U.S. LLC | 1 | $98 |
| Janssen Scientific Affairs, LLC | 1 | $80 |
| Helsinn Therapeutics (U.S.), Inc. | 3 | $62 |
| Sun Pharmaceutical Industries Inc. | 2 | $58 |
| Amgen | 1 | $55 |
| Pfizer | 3 | $54 |
| UCB, Inc. | 2 | $41 |
| Cipher Pharmaceuticals US LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$40,726 in reported general payments places this provider in the 90th percentile of 626 dermatology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 81 | $680,510 |
| Dupixent PenDupilumab | 104 | $372,980 |
| Humira PenAdalimumab | 17 | $181,593 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 14 | $93,975 |
| Humira(Cf)Adalimumab | 11 | $74,927 |
| XolairOmalizumab | 25 | $66,245 |
| Dupixent SyringeDupilumab | 18 | $64,668 |
| Hydrocortisone | 17 | $63 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieHumira(Cf) | $1,003 | $74,92711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 626 dermatology providers in Pennsylvania.
Other dermatology in Philadelphia
- Stephen HessPhiladelphia$1.7M
- Joel GelfandPhiladelphia$649K
- Victoria WerthPhiladelphia$547K
- Nicholas MollanazarPhiladelphia$369K
- Harold FarberPhiladelphia$284K
- Jules LipoffPhiladelphia$259K
- Susan TaylorPhiladelphia$207K
- Joy WanPhiladelphia$176K
- Harold MilsteinPhiladelphia$120K
- David MargolisPhiladelphia$118K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.